Structural Heart Devices Market Overview and Business Intelligence
Growth in the structural heart devices market
is mainly driven by factors such as the rising prevalence of structural
heart diseases, regulatory approvals for new and advanced structural
heart devices, favorable reimbursement scenario for structural heart
procedures & devices, and increasing awareness about structural
heart diseases.
According to research report the global
structural heart devices market is projected to reach USD 15.08 billion
by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753
•
On the basis of procedure, the market has been broadly segmented into
replacement procedures and repair procedures. The replacement procedures
segment is further segmented into TAVR (transcatheter aortic valve
replacement) procedures and SAVR (surgical aortic valve replacement)
procedures, while the repair procedures segment is subdivided into
closure procedures, annuloplasty, valvuloplasty, and TMVR procedures.
•
On the basis of products, the structural heart devices market is
segmented into heart valve devices, occluders and delivery systems,
annuloplasty rings, other devices, and accessories. The heart valve
devices segment is further subdivided into transcatheter heart valves
and surgical heart valves.
Players in this market compete with
each other to deliver superior and advanced technologies for heart valve
repair and replacement. In 2017, the structural heart devices market
was dominated by a few large players, namely, Edwards Lifesciences
Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston
Scientific Corporation (US), and LivaNova plc (UK).
Product
launches & approvals; acquisitions; expansions; and partnerships
& agreements were the key strategies adopted by key players between
2015 and 2018. Some of the key players that adopted these strategies are
Edwards Lifesciences (US), Medtronic (Ireland), Boston Scientific (US),
Abbott (US), LivaNova (UK), Micro Interventional Devices (US), Braile
Biomédica (Brazil), and CryoLife (US).
> Edwards Lifesciences
held the leading position in the global structural heart devices market
in 2017 on account of its diverse portfolio of transcatheter and
surgical heart valves.
> Medtronic held the second position in
the structural heart devices market in 2017. The company offers a
comprehensive range of transcatheter and surgical heart valve products
through its Coronary & Structural Heart division. The key
percutaneous surgical products offered by the company include the
third-generation CoreValve Evolut PRO system and tissue & mechanical
heart valves.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=161123753
Geographically,
North America is expected to account for the largest share of the
structural heart devices market in 2018, followed by Europe. The large
share of North America in the global market is attributed to factors
such as the rising prevalence of structural heart diseases, favorable
reimbursement scenario for structural heart procedures and devices,
technological advancements, and development of innovative devices.
Comments
Post a Comment